Kiadis Pharma (KIADF) Stock Price, News & Analysis

Company Overview

Kiadis Pharma SA is a clinical‐stage biopharmaceutical company focused on the development of allogeneic cell‐based immunotherapies for the treatment of cancer. The company leverages both T cells and natural killer (NK) cells to create off‐the‐shelf, donor‐derived products aimed at enhancing graft‐versus‐tumor activity while minimizing graft‐versus‐host disease in patients undergoing stem cell transplantation and beyond.

The company’s lead programs include ATIR101, an allogeneic T‐cell product designed to accompany hematopoietic stem cell transplantation in acute leukemia patients, and a next‐generation portfolio of NK cell therapies—branded as K-NK001, K-NK002 and K-NK003—targeting hematologic malignancies such as acute myeloid leukemia (AML) and certain solid tumors. Kiadis has also established a modular manufacturing platform to produce cryopreserved, ready‐to‐infuse cell therapy products, enabling broader and faster patient access.

Founded in the Netherlands in 2008 and headquartered in Amsterdam, Kiadis Pharma has conducted early‐ and mid‐phase clinical trials in Europe and North America. The company’s research collaborations and strategic partnerships support scalable production and aim to accelerate clinical development across multiple oncology indications. Kiadis maintained a primary listing on European exchanges and an over‐the‐counter quotation in the United States to facilitate international investor access.

Key Stats

• Today's Range: $6.41 to $6.41
• 50-Day Range: $6.41 to $6.41
• 52-Week Range: $1.72 to $6.55
• Volume: N/A
• Average Volume: 1,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:KIADF
• CIK: N/A
• Web: www.kiadis.com
• Phone: 31 20 240 5250
• Fax: N/A
• Employees: 103
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A